Repligen (RGEN)
(Real Time Quote from BATS)
$115.68 USD
-0.82 (-0.70%)
Updated Aug 5, 2025 02:18 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Repligen Corporation has a market cap of $6.55B, which represents its share price of $116.50 multiplied by its outstanding shares number of 56.18M. As a mid-cap company, RGEN's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
RGEN 115.68 -0.82(-0.70%)
Will RGEN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RGEN
Repligen (RGEN) Lags Q2 Earnings Estimates
Here's Why Repligen (RGEN) is a Strong Growth Stock
RGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Do Options Traders Know Something About Repligen (RGEN) Stock We Don't?
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
QGEN or RGEN: Which Is the Better Value Stock Right Now?
Other News for RGEN
Repligen Stock Outlook: Risk Skewed To The Downside Through 2026
Repligen partners with Novasign to use ML in filtration systems
Repligen (RGEN) Partners with Novasign to Enhance Filtration Systems
Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing ...
Repligen announces strategic partnership with Novasign